Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study

Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study

<i>Background and Objectives:</i> The comparative efficacy and safety of nivolumab plus ipilimumab (Nivo-Ipi) combination therapy between patients with either postoperative recurrent non-small cell lung cancer (NSCLC) or inoperable stage III/IV NSCLC have yet to be conclusively determine...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuhei Kurata, Atsuto Mouri, Hisao Imai, Satoshi Endo, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Medicina
Subjects:
advanced non-small cell lung cancer
immune checkpoint inhibitor
ipilimumab
nivolumab
postoperative recurrence
Online Access:https://www.mdpi.com/1648-9144/61/6/994
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items